{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:55:29Z","timestamp":1785542129280,"version":"3.56.0"},"reference-count":15,"publisher":"Texas Heart Institute Journal","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>Patients with Friedreich ataxia typically die of cardiomyopathy, marked by myocardial fibrosis and abnormal left ventricular (LV) geometry. We measured procollagen I carboxyterminal propeptide (PICP), a serum biomarker of collagen production, and characterized genotypes, phenotypes, and outcomes in these patients.<\/jats:p>\n        <jats:p>Twenty-nine patients with Friedreich ataxia (mean age, 34.2 \u00b1 2.2 yr) and 29 healthy subjects (mean age, 32.5 \u00b1 1.1 yr) underwent serum PICP measurements. Patients underwent cardiac magnetic resonance imaging and outcome evaluations at baseline and 12 months.<\/jats:p>\n        <jats:p>Baseline PICP values were significantly higher in the patients than in the control group (1,048 \u00b1 77 vs 614 \u00b1 23 ng\/mL; <jats:italic>P<\/jats:italic> &lt;0.001); severity of genetic abnormality did not indicate severity of PICP elevation. Higher PICP levels corresponded to greater LV concentric remodeling only at baseline (<jats:italic>r<\/jats:italic>=0.37, <jats:italic>P<\/jats:italic> &lt;0.05). Higher baseline PICP strongly indicated subsequent increases in LV end-diastolic volume (<jats:italic>r<\/jats:italic>=0.52, <jats:italic>P<\/jats:italic>=0.02). The PICP levels did not distinguish between 14 patients with evident myocardial fibrosis identified through positive late gadolinium enhancement and 15 who had no enhancement (1,067 \u00b1 125 vs 1,030 \u00b1 98 ng\/mL; <jats:italic>P<\/jats:italic>=0.82). At 12 months, cardiac events had occurred in 3 of 14 fibrosis-positive and none of 15 fibrosis-negative patients (<jats:italic>P<\/jats:italic>=0.1); their baseline PICP levels were similar.<\/jats:p>\n        <jats:p>We conclude that PICP, a serum marker of collagen synthesis, is elevated in Friedreich ataxia and indicates baseline abnormal LV geometry and subsequent dilation. Cardiac magnetic resonance and PICP warrant consideration as complementary biomarkers in therapeutic trials of Friedreich ataxia cardiomyopathy.<\/jats:p>","DOI":"10.14503\/thij-14-4198","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T21:08:19Z","timestamp":1470431299000},"page":"305-310","source":"Crossref","is-referenced-by-count":10,"title":["Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes"],"prefix":"10.14503","volume":"43","author":[{"given":"Nishaki","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha V.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5628","reference":[{"issue":"4","key":"i1526-6702-43-4-305-b1","series-title":"Ir J Med Sci","first-page":"799","article-title":"Friedreich's ataxia: a review from a cardiology perspective","volume":"180","year":"2011","unstructured":"Bourke\n              T, \n            \n              Keane\n              D.\n            \n          \n          Friedreich's ataxia: a review from a cardiology perspective. Ir J Med Sci2011;180(4):799\u2013805."},{"issue":"1","key":"i1526-6702-43-4-305-b2","series-title":"J Med Genet","first-page":"1","article-title":"Friedreich ataxia: an overview","volume":"37","year":"2000","unstructured":"Delatycki\n              MB, \n            \n              Williamson\n              R, \n            \n              Forrest\n              SM.\n            \n          \n          Friedreich ataxia: an overview. J Med Genet2000;37(1):1\u20138."},{"issue":"6","key":"i1526-6702-43-4-305-b3","series-title":"J Neurol","first-page":"345","article-title":"Genetic data and natural history of Friedreich's disease: a study of 80 Italian patients","volume":"237","year":"1990","unstructured":"Filla\n              A, \n            \n              DeMichele\n              G, \n            \n              Caruso\n              G, \n            \n              Marconi\n              R, \n            \n              Campanella\n              G.\n            \n          \n          Genetic data and natural history of Friedreich's disease: a study of 80 Italian patients. J Neurol1990;237(6):345\u201351."},{"issue":"1\u20132","key":"i1526-6702-43-4-305-b4","series-title":"J Neurol Sci","first-page":"46","article-title":"Mortality in Friedreich ataxia","volume":"307","year":"2011","unstructured":"Tsou\n              AY, \n            \n              Paulsen\n              EK, \n            \n              Lagedrost\n              SJ, \n            \n              Perlman\n              SL, \n            \n              Mathews\n              KD, \n            \n              Wilmot\n              GR, \n          \n          et al. Mortality in Friedreich ataxia. J Neurol Sci2011;307(1\u20132):46\u20139."},{"issue":"3","key":"i1526-6702-43-4-305-b5","series-title":"Acta Neurol Belg","first-page":"183","article-title":"Cardiomyopathy in Friedreich's ataxia","volume":"111","year":"2011","unstructured":"Rahman\n              F, \n            \n              Pandolfo\n              M.\n            \n          \n          Cardiomyopathy in Friedreich's ataxia. Acta Neurol Belg2011;111(3):183\u20137."},{"issue":"5","key":"i1526-6702-43-4-305-b6","series-title":"Eur Heart J","first-page":"561","article-title":"Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome","volume":"32","year":"2011","unstructured":"Raman\n              SV, \n            \n              Phatak\n              K, \n            \n              Hoyle\n              JC, \n            \n              Pennell\n              ML, \n            \n              McCarthy\n              B, \n            \n              Tran\n              T, \n          \n          et al. Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur Heart J2011;32(5):561\u20137."},{"issue":"9","key":"i1526-6702-43-4-305-b7","series-title":"Can J Cardiol","first-page":"523","article-title":"Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology","volume":"25","year":"2009","unstructured":"Li\n              MJ, \n            \n              Huang\n              CX, \n            \n              Okello\n              E, \n            \n              Yanhong\n              T, \n            \n              Mohamed\n              S.\n            \n          \n          Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol2009;25(9):523\u20136."},{"issue":"8","key":"i1526-6702-43-4-305-b8","series-title":"J Hypertens","first-page":"1445","article-title":"The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease","volume":"23","year":"2005","unstructured":"Lopez\n              B, \n            \n              Gonzalez\n              A, \n            \n              Querejeta\n              R, \n            \n              Diez\n              J.\n            \n          \n          The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens2005;23(8):1445\u201351."},{"issue":"3","key":"i1526-6702-43-4-305-b9","series-title":"Circ Cardiovasc Imaging","first-page":"243","article-title":"The prognostic implications of cardiovascular magnetic resonance","volume":"2","year":"2009","unstructured":"Flett\n              AS, \n            \n              Westwood\n              MA, \n            \n              Davies\n              LC, \n            \n              Mathur\n              A, \n            \n              Moon\n              JC.\n            \n          \n          The prognostic implications of cardiovascular magnetic resonance. Circ Cardiovasc Imaging2009;2(3):243\u201350."},{"issue":"15","key":"i1526-6702-43-4-305-b10","series-title":"Circulation","first-page":"1623","article-title":"The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy","volume":"128","year":"2013","unstructured":"Gulati\n              A, \n            \n              Ismail\n              TF, \n            \n              Jabbour\n              A, \n            \n              Alpendurada\n              F, \n            \n              Guha\n              K, \n            \n              Ismail\n              NA, \n          \n          et al. The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. Circulation2013;128(15):1623\u201333."},{"issue":"1","key":"i1526-6702-43-4-305-b11","series-title":"Phys Med Rehabil Clin N Am","first-page":"145","article-title":"Management of cardiac complications in neuromuscular disease","volume":"9","year":"1998","unstructured":"Lewis\n              WR, \n            \n              Yadlapalli\n              S.\n            \n          \n          Management of cardiac complications in neuromuscular disease. Phys Med Rehabil Clin N Am1998;9(1):145\u201366, vii."},{"issue":"1\u20132","key":"i1526-6702-43-4-305-b12","series-title":"J Neurol Sci","first-page":"1","article-title":"Friedreich's ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","year":"2011","unstructured":"Koeppen\n              AH.\n            \n          \n          Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci2011;303(1\u20132):1\u201312."},{"issue":"5","key":"i1526-6702-43-4-305-b13","series-title":"Hypertension","first-page":"1222","article-title":"Biochemical assessment of myocardial fibrosis in hypertensive heart disease","volume":"38","year":"2001","unstructured":"Lopez\n              B, \n            \n              Gonzalez\n              A, \n            \n              Varo\n              N, \n            \n              Laviades\n              C, \n            \n              Querejeta\n              R, \n            \n              Diez\n              J.\n            \n          \n          Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension2001;38(5):1222\u20136."},{"issue":"3","key":"i1526-6702-43-4-305-b14","series-title":"Am J Hum Genet","first-page":"554","article-title":"The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia","volume":"59","year":"1996","unstructured":"Filla\n              A, \n            \n              De Michele\n              G, \n            \n              Cavalcanti\n              F, \n            \n              Pianese\n              L, \n            \n              Monticelli\n              A, \n            \n              Campanella\n              G, \n            \n              Cocozza\n              S.\n            \n          \n          The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet1996;59(3):554\u201360."},{"issue":"1","key":"i1526-6702-43-4-305-b15","series-title":"Curr Opin Rheumatol","first-page":"90","article-title":"Immunopathology, musculoskeletal features, and treatment of sarcoidosis","volume":"5","year":"1993","unstructured":"Mathur\n              A, \n            \n              Kremer\n              JM.\n            \n          \n          Immunopathology, musculoskeletal features, and treatment of sarcoidosis. Curr Opin Rheumatol1993;5(1):90\u20134."}],"container-title":["Texas Heart Institute Journal"],"original-title":[],"link":[{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/43\/4\/article-p305.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/thij\/article-pdf\/43\/4\/305\/1971394\/thij-14-4198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/43\/4\/article-p305.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/43\/4\/article-p305.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:32:30Z","timestamp":1730993550000},"score":1,"resource":{"primary":{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/43\/4\/article-p305.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":15,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.14503\/thij-14-4198","relation":{},"ISSN":["0730-2347","1526-6702"],"issn-type":[{"value":"0730-2347","type":"print"},{"value":"1526-6702","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}